Dublin, June 05, 2018 (GLOBE NEWSWIRE) -- The "Global Bi-Specific Antibodies Market Forecast to 2022" report has been added to ResearchAndMarkets.com's offering.
The bi-specific antibodies intend to provide the next generation of targeted biologics by engaging two different targets simultaneously. These drugs offer several advantages over traditional treatment options for various diseases such as cancer. They have fewer side effects due to high specificity towards disease target. Bi-specific antibody is one of the most potentially powerful tools which have emerged in the biopharmaceutical industry. The bi-specific antibodies intend to provide the next generation of targeted biologics by engaging two different targets simultaneously. These drugs offer several advantages over traditional treatment options for various diseases such as cancer. They have fewer side effects due to high specificity towards disease target. These antibodies are of particular importance for patients who experience recurrence or resistance to drugs. According to this report titled Global Bi-Specific Antibodies Market Forecast to 2022, the Global Bi-Specific Antibodies Market is anticipated to witness a double digit growth during the forecast period. The report provides information about the current and future scenario of this market. The report also highlights the major drivers, such as increasing incidences of diseases and increasing demand for effective treatment, for the Global Bi-Specific Antibodies Market. Furthermore, the report also gives information related to the commercially available bi-specific antibody drugs. Moreover, few hindrances, such as production hurdles and regulatory challenges, which are slowing down the growth of the Global Bi-Specific Antibodies Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market. Furthermore, in this report, we have structured the information regarding bi-specific antibodies at various stages of clinical development. The pipeline chapter provides in depth analysis of bi-specific antibodies by clinical phase, indications for which they are being developed, and technology. Additionally, the study provides all-inclusive current analysis of various bi-specific antibodies in advanced as well as early stages of development. Moreover, our report places emphasis on the strategic collaborations that can impact industry's growth. The prominent players in Global Bi-Specific Antibodies Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Global Bi-Specific Antibodies Market.
Key Topics Covered:
1. Analyst View 2. Research Methodology 3. Bi-Specific Antibodies - An Introduction 4. Global Bi-Specific Antibodies Market Outlook to 2022 4.1 BLINCYTO 4.2 Hemlibra 4.3 Removab 5. Bi-Specific Antibodies Pipeline Analysis 5.1 By Clinical Phase 5.2 By Indication 5.3 By Technology 6. Market Dynamics 6.1 Drivers 6.1.1 Rising Global Cancer Epidemics 6.1.2 Bi-Specific Antibodies Improving the Targeting Capabilities of Traditional mAbs 6.1.3 T-cells in Bi-Specific Antibodies Mediated Immunotherapy 6.1.4 Increasing Demand for Bi-Specific/Double Barreled Antibodies 6.2 Challenges 6.2.1 Production Hurdles in Bi-Specific Antibodies Development 6.2.2 Regulatory Challenges 7. Current Status of Major Bi-Specific Antibodies in Pipeline 7.1 BLINCYTO/Blinatumomab - Amgen Inc. 7.2 ABT-122 - AbbVie Inc. 7.3 MCLA-128 - Merus N.V. 7.4 ALX-0761/M1095 - Ablynx 7.5 MGD006/S80880 - MacroGenics, Inc. 7.6 ZW25 - Zymeworks Inc. 8. Trends and Developments 8.1 Bi-specific Antibody Application for Tumor Therapy 8.2 Bi-specific Antibodies Development Against Myeloma 8.3 Bi-specific Antibody Agreement with EpimAb Biotherapeutics 8.4 B-specific Antibody Development against Multiple Ebola viruses 9. Strategic Collaborations in the Bi-Specific Antibodies Industry
10. Competitive Assessment 10.1 Amgen Inc. 10.2 F. Hoffman La Roche Ltd. 10.3 AbbVie Inc. 10.4 OncoMed Pharmaceuticals, Inc. 10.5 Glenmark Pharmaceuticals Limited 10.6 Xencor, Inc. 10.7 MacroGenics, Inc. 10.8 Aptevo Therapeutics Inc. 10.9 Ligand Pharmaceuticals, Inc. 10.10 Regeneron Pharmaceuticals, Inc. 10.11 Fresenius SE & Co. KGaA 10.12 Merus N.V.
For more information about this report visit https://www.researchandmarkets.com/research/t...lobal?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Immune Disorders Drugs
